MAUI, Hawaii — Interleukin-23 inhibitors are effective for induction and maintenance of remission in Crohn’s disease and ulcerative colitis, according to an expert at the GUILD Conference 2020.

“So we have all these great new mechanisms and, this year at GUILD, we wanted to take some time to delve into some of them,” Uma Mahadevan, MD, professor of medicine at UCSF Colitis and Crohn’s Disease, said during a presentation.

Mahadevan cited a study that found that 66% of patients with CD who were in remission at week 0 were still in remission at week 44 after receiving

Full Article: